Use of induced sputum CC16 as a predictive marker for severity of COPD and eosinophilic subtypes
By detecting CC16 mRNA expression levels in induced sputum and constructing a diagnostic model in conjunction with FEV1%pred values, the problem of difficulty in assessing COPD severity and inflammatory phenotype was solved, enabling more accurate COPD assessment and personalized treatment.
CN116287215BActive Publication Date: 2026-05-29ZHONGSHAN HOSPITAL FUDAN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGSHAN HOSPITAL FUDAN UNIV
- Filing Date
- 2023-03-28
- Publication Date
- 2026-05-29
Smart Images
Figure CN116287215B_ABST
Abstract
The application discloses an application of inducing sputum CC16 as a prediction marker of COPD severity and eosinophil subtype. The application finds that the expression of CC16 in induced sputum of mild and moderate COPD patients and severe and very severe COPD patients has significant difference by detecting and analyzing various inflammatory molecules in induced sputum, and can distinguish eosinophilic COPD. The application establishes a regression model based on FEV1pred% and the relative expression level of CC16 mRNA, and the model has good sensitivity, specificity and accuracy. Therefore, the mRNA level of induced sputum CC16 has good application prospect for evaluating the severity of COPD and diagnosing the eosinophil subtype. The application can evaluate the severity of COPD and diagnose the eosinophil subtype in a more simple way, and based on the characteristics of the biomarker, a more reliable non-invasive kit can be prepared.
Need to check novelty before this filing date? Find Prior Art